Новости фармакогенетики - гены ожирения, капецитабин

Врач-онколог Федоринов Денис Сергеевич Источники литературы: Melisi D, Zecchetto C, Merz V, Malleo G, Landoni L, Quinzii A, Casalino S, Fazzini F, Gaule M, Pesoni C, Casetti L, Esposito A, Marchegiani G, Piazzola C, D’Onofrio M, de Robertis R, Gabbrielli A, Bernardoni L, Crino SF, Pietrobono S, Luchini C, Aliberti C, Martignoni G, Milleri S, Butturini G, Scarpa A, Salvia R, Bassi C. Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial. Eur J Cancer. 2023 Nov 11;196:113430. doi: Epub ahead of print. PMID: 37995598. Paszkowiak M, Dorand MF, Richards J. Case report of PLXNA4 variant associated with hyper-response to phentermine/topiramate pharmacotherapy: Potential genetic basis for superior weight loss response? Obes Pillars. 2023 Feb 21;5:100059. doi: PMID: 37990741; PMCID: PMC10662083. Cura Y, Sánchez-Martín A, Márquez-Pete N, González-Flores E, Martínez-Martínez F, Pérez-Ramírez C, Jiménez-Morales A. Association of Single-Nucleotide Polymorphisms in Capecitabine Bioactivation Pathway with Adjuvant Therapy Safety in Colorectal Cancer Patients. Pharmaceutics. 2023 Oct 28;15(11):2548. doi: PMID: 38004528; PMCID: PMC10675271.